GTx Inc., of Memphis, Tenn., reported data from a Phase IIb study showing that enobosarm, a selective androgen-receptor modulator, may play a role in the management of cancer patients with muscle wasting by improving physical function. Of the 159 subjects randomized to the study, 103 had physical function assessed at both baseline and following 16 weeks of treatment.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST